Russia's COVID-19 Vaccine Under Development Completes Phase 2 Clinical Trials

[Image source=Yonhap News]

[Asia Economy Reporter Choi Dong-hyun] It has been reported that the new coronavirus disease (COVID-19) vaccine being developed by the Russian Ministry of Defense has completed its Phase 2 clinical trials.

On the 21st (local time), Bloomberg cited a statement from a senior official of the Russian Ministry of Defense in the Moscow weekly magazine 'Argumenty i Fakty' reporting this. The senior official said, "Phase 2 clinical trials were completed on the 20th," adding, "All participants in the trial have developed immunity against COVID-19 and feel healthy." He reportedly did not mention when Phase 3 clinical trials would begin or when the vaccine would be produced.

Currently, the Gamaleya Center in Russia is promoting vaccine development with investment from Russia's sovereign wealth fund, the Russian Direct Investment Fund (RDIF), and support from the Ministry of Defense. The Phase 1 clinical trials, conducted on 38 volunteers each at Moscow's Sechenov Medical University and Burdenko Military Hospital, began in June and were completed in mid-month.

Kiril Dmitriev, CEO of RDIF, which invested in vaccine development, stated last week that Phase 3 clinical trials targeting citizens of Russia, Saudi Arabia, and the United Arab Emirates (UAE) would begin in August, and that the vaccine could be supplied by September.

This content was produced with the assistance of AI translation services.